NCT01574313

Effect of Stellate Ganglion Block on Meniere's Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Chi Mei Medical Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Stellate ganglion block (SGB) has been the alternative treatment of Meniere's disease for years. However, objective evidence of the effect of SGB was still lack. The investigators conducted a randomized controlled study to examine the immediate effects of SGB in SP/AP of electrocochleography (ECoG).

Detailed description

Ten patients were randomly assigned to receive stellate ganglion block. These ten patients made up the experimental group. Another ten patients in the control group were assigned to receiving one dosage of oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).

Conditions

• Vertigo
• Meniere Disease

Interventions

Type	Name	Description
PROCEDURE	stellate ganglion block	stellate ganglion block
DRUG	0.25mg, fludiazine	0.25mg of erispan@ (fludiazine), p.o. one dose only.
DRUG	25mg cephadol@ (diphenidol)	25mg cephadol@ (diphenidol) p.o. one dose only.
DRUG	200mg kentons@ (tocopherol nicotinate).	200mg kentons@ (tocopherol nicotinate) p.o. one dose only.

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-04-01
• Completion: 2012-03-01
• First posted: 2012-04-10
• Last updated: 2012-04-11

Locations

1 site across 1 country: Taiwan